The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2024

Filed:

Sep. 09, 2022
Applicant:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Liyi Geng, Rochester, MN (US);

Ping Chen, Rochester, MN (US);

William S. Brimijoin, Rochester, MN (US);

Yang Gao, Rochester, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/18 (2006.01); C07K 14/00 (2006.01); C07K 14/575 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 38/00 (2006.01); A61K 38/22 (2006.01); A61K 48/00 (2006.01); C07H 21/04 (2006.01); C12N 15/861 (2006.01); C12N 15/864 (2006.01);
U.S. Cl.
CPC ...
C12N 9/18 (2013.01); C07K 14/00 (2013.01); C07K 14/5759 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12Y 301/01008 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 38/00 (2013.01); A61K 38/2264 (2013.01); A61K 48/00 (2013.01); C07H 21/04 (2013.01); C12N 15/861 (2013.01); C12N 15/8645 (2013.01); C12N 2750/14141 (2013.01); C12N 2750/14143 (2013.01);
Abstract

This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.


Find Patent Forward Citations

Loading…